This Monday, Bio-Thera Solutions and Dr. Reddy’s Laboratories SA announced that they had entered into commercialization and licensing agreements for proposed ustekinumab and golimumab ...

Under the Healthcare Common Procedure Coding System (HCPCS), the Q-code Q9999 is for "Injection, for subcutaneous use or intravenous use, ustekinumab-aauz (Otulfi), biosimilar per 1.0 mg." ...

Otulfi is FDA-approved for subcutaneous and intravenous formulations to treat the same conditions as Stelara (ustekinumab), including Crohn’s disease, ulcerative colitis, moderate to severe plaque ...

The company is known for products such as Darzalex, Stelara, and Tremfya. Its MedTech segment offers medical devices across orthopaedics, surgery, and vision care. JNJ ranked eighth on our recent ...

Johnson & Johnson (J&J) has announced that Stelara (ustekinumab) has been approved by the European Commission (EC) to treat moderately to severely active Crohn’s disease (CD) in paediatric patients.

The debuts of lower-cost biosimilars for AbbVie's rheumatoid arthritis drug Humira in 2023 and Janssen’s immunology medication Stelara this year, which cost about $7,000 and $10,000 a month ...

The concerns around the Stelara exclusivity appear overblown. China’s new tariffs just reignited the same market patterns that led to triple- and quadruple-digit wins for Matt Maley. Get the ...

CEO Joaquin Duato cited 4.2% operational sales growth in innovative medicine, despite the negative impact from biosimilar competition for STELARA, and emphasized the company’s strong product launches ...